Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.

ABSTRACT: BACKGROUND:Specific clinical risk factors may contribute to improving or worsening neurological functions in acute ischemic stroke (AIS) patients pre-treated with a combined cholesterol reducer and recombinant tissue plasminogen activator (rtPA) therapy. In this study, clinical risk factors associated with good or poor presenting neurological symptoms in ischemic stroke patients with prior cholesterol reducer use, specifically a statin and rtPA therapy was investigated. METHODS:Retrospective data for baseline clinical and demographic data for patients with AIS taking cholesterol reducers prior to rtPA treatment from January 2010 to June 2016 in a regional stroke center was analyzed. Improving (NIHSS score???7) or worsening (NIHSS score?>?7) of neurologic functions were the determined measures of treatment outcome. Multivariate logistic regression models identified demographic and clinical factors associated with worsening or improving neurologic functions. RESULTS:Adjusted multivariate analysis showed that in an AIS population with a combined rtPA and cholesterol reducer medication history, increasing age (OR?=?1.032, 95% CI, 1.015-1.048, P 

SUBMITTER: Poupore N 

PROVIDER: S-EPMC7201805 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature